Affimed Gmbh

Amphivena Therapeutics, Inc.

Erich Rajkovic

Uwe Reusch

Kristina Ellwanger

Ivica Fucek

Martin Treder

Michael Weichel

Stefan Knackmuss

Thorsten Ross

Luke Evnin

Melvyn Little

Jeanmarie Guenot

Lori Kunkel

Judith A Fox

Eugene Zhukovsky

Vera Molkenthin

Claudia Wall

Michael Tesar

Joachim Koch

Michael Kluge

Michael Damrat

Adelheid Cerwenka

Jens Pahl

Thomas Mueller

The invention relates to a multispecific antigen-binding molecule specifically binding to CD16A and consisting of two polypeptide chains, wherein each polypeptide chain comprises at least four variable domains from the N-terminus to the C-terminus in the order: VH_BCMA-VL_CD16A-VH_CD16A-VL_BCM.

Tandem diabody for CD16A-directed NK-cell engagement

Described are tetravalent, bispecific EGFR/CD16A antigen-binding proteins for engaging NK-cells towards EGFR-positive cells. EGFR/CD16A antigen-binding proteins with different pharmacokinetic (PK) properties are described. Further described is the use of bispecific EGFR/CD16A antigen-binding proteins for the treatment of an EGFR-positive malignancy, such as EGFR-positive tumors.

Bispecific EGFR/CD16 antigen-binding protein

The application pertains to a trispecific antibody molecule which may comprise a diabody-unit integrated into a polypeptide chain having at least six variable domains linked one after another. In certain instances two single-chain Fv (scFv) fragments are distally connected to the diabody-unit providing two further antigen binding sites (FIGS.and).

Multivalent FV antibodies

The invention relates to an anti-CD16A antigen binding protein for use in NK cell-based immunotherapy, wherein the anti-CD16A antigen binding protein is to be administered intermittently and in combination with a cytokine. In certain embodiments the antigen binding protein is a tetravalent and bispecific CD30/CD16A tandem diabody.

Combination of an anti-CD16A antibody with a cytokine

The invention relates to multispecific antigen-binding proteins for engaging natural killer (NK) cells for triggering NK cell cytotoxicity by engaging the CD16A (Fc&#x3b3;RIIIA) expressed on NK cells, wherein the antigen-binding protein comprises at least two CD16A antigen-binding moieties and at least a further target antigen-binding moiety. The CD16A antigen-binding moiety comprises light chain and heavy chain variable regions linked one after another in a polypeptide chain and the variable region at the N-terminus of the polypeptide chain comprising the CD16A antigen-binding moiety is a light chain variable region.

NK cell engaging antibody fusion constructs

Described herein are binding proteins that specifically bind to human CD33, and in particular to bispecific binding proteins that specifically bind to human CD33 and human CD3. Also described herein are bispecific tandem diabodies that bind to CD33 and CD33, and their uses for immunotherapy of CD33cancers, diseases and conditions such as acute myeloid leukemia (AML).

Bispecific CD33 and CD3 binding proteins

Growing community of inventors

Schriesheim, Germany

Erich Rajkovic